CA-PACSCI-EMC
17.3.2020 15:02:07 CET | Business Wire | Press release
Pacific Scientific Energetic Materials Company (California), LLC. (PacSci EMC) announced today the execution of a Memorandum of Understanding with Space Information Laboratories (SIL) to provide plug-and-play Autonomous Flight Termination Systems (AFTS) for launch vehicles, missiles, hypersonic vehicles, reentry vehicles, strike weapons and unmanned aerial systems. PacSci EMC Safe and Arm high voltage electronics will be integrated with the SIL Vehicle Based Independent Tracking System (VBITS) AFTU with internal GPS L1/L2 Receivers, IMU, together in a Consolidated Avionics® unit with reduced Space, Weight and Power (SWAP) requirements. Attributes include open, modular, stackable and reconfigurable (OMSR) avionics.
“SIL has very unique, leading-edge technology for the AFSS mission that when combined with the PacSci EMC flight qualified ordnance flight termination system provides a low cost, comprehensive solution for this critical need,” said Greg Scaven, President, PacSci EMC. “The AFSS architecture is RCC-319 compliant with the flexibility and safety necessary for platform success, and the system can be customized for unique applications.”
SIL is a leading provider of high-end Li-Ion Polymer Intelli-Pack® Avionics/Telemetry and FTS Batteries, VBITS GPS Tracking and Autonomous Flight Termination Systems (AFTS), Space Based Range, and Consolidated Avionics® flight units for DoD programs of national significance. Originally developed in 2006, VBITS has successfully flown many times without loss of GPS receiver lock and this heritage is being leveraged. SIL’s patented Vehicles Based Independent Range System (VBIRS) will track, destroy and send high data rate BLOS telemetry without the need for ground range instrumentation Radar, Flight Termination and/or Telemetry Systems, and thus greatly reduces launch, and weapon system test and evaluation, costs.
Edmund Burke, President of Space Information Laboratories, said: “I am very impressed with PacSci EMC’s broad product offering and technical capabilities. They rapidly filled a need for us that will result in accelerated growth.”
About Pacific Scientific Energetic Materials Co.
PacSci EMC provides state-of-the-art safe and arm high voltage electronics firing circuitry for multiple DoD and commercial launch vehicle, missile, weapons and aircraft. PacSci EMC missile control safety and arming products are suitable for application in all weapon systems. PacSci EMC has seven decades of pyrotechnic and energetic materials experience for mission and flight critical safety systems. (https://psemc.com )
About Space Information Laboratories
Headquartered in Santa Maria, CA near Vandenberg AFB, SIL is a world-class small business supplier of innovative avionics and power system technologies and solutions for mission-critical programs for the MDA, NAVAIR, USAF, DARPA, Aerospace Industry, and other U.S. Government Agencies. SIL’s expertise includes development and production of Li-Ion Polymer Intelli-Pack® batteries, Intelli-Avionics®, VBITS GPS Tracking and Autonomous Flight Termination System, Space Based Range and Chameleon 12U to 27U Flexible Bus product lines. SIL is AS9100D Quality Management System certified to design, manufacture and test flight units. (www.spaceinformationlabs.com )
View source version on businesswire.com: https://www.businesswire.com/news/home/20200317005002/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom